SecBot SecBot
SECBOTREPLAY Home › Report › ACRV

ACRV · Acquires JAK1 inhibitor ACR-525

Acrivon Therapeutics, Inc · PRESS-RELEASE filed Nov 6, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 6, 2026 at 08:00 ET

Acrivon Therapeutics acquired ACR-525 (Phase 2-ready oral JAK1 inhibitor) and a preclinical PKCθ inhibitor program from Aqilion AB for an undisclosed cash consideration, with no future royalties or milestones. The deal establishes immunology and inflammation as a new strategic pillar alongside oncology, targeting eosinophilic esophagitis as the first indication. The transaction closed concurrently with signing and was approved by both companies' boards.

  • Acrivon acquired ACR-525 (Phase 2-ready oral JAK1 inhibitor) and a preclinical PKCθ inhibitor program from Aqilion AB.
  • Consideration was undisclosed cash with no future royalties or milestone obligations.
  • Eosinophilic esophagitis (EoE) targeted as first potential indication using a Phase 2-ready formulation.
  • Transaction closed concurrently with signing; approved by both boards.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access